Barclays analyst Etzer Darout initiates coverage on Forte Biosciences (NASDAQ:FBRX) with a Overwe

Gainers EUDA Health Holdings (NASDAQ:EUDA) shares rose 22.3% to $15.2 during Friday's regular s

Forte Biosciences stock soars after early-stage data show FB102 significantly improves facial depigm

Forte Biosciences NASDAQ: FBRX said FB102 showed statistically significant improvement in a small pl

Dow Jones index up 50 points, Equipmentshare.Com up 15.4% on revenue guidance increase and share rep

Forte Biosciences (FBRX) offers upside as FB102 demonstrates efficacy in both celiac disease and vit

Forte Biosciences, Inc. (FBRX) Discusses Positive Results From FB102 Phase 1b Vitiligo Study and Mec

Forte Biosciences (NASDAQ:FBRX) shares jumped about 55% after the company reported positive phase 1b

Gainers Virax Biolabs Group (NASDAQ:VRAX) shares rose 178.9% to $8.87 during Thursday's regular

Read Also: Teva Reports Early Skin Repigmentation Data, Sets Stage For Next Trial

Forte Biosciences reported positive Phase 1b vitiligo data, with FB102 showing significant facial re

U.S. stocks higher, Dow gains over 150 points. NASDAQ up 0.84%, S&P 500 up 0.60%. Tech shares ju

U.S. stocks higher, Nasdaq up 150+ points. Aehr Test Systems shares rose 13.6%. Other big gainers in

Forte Biosciences (NASDAQ:FBRX) shares jumped about 55% after the company reported positive phase 1b

Forte Biosciences, Inc. ([url="]www.fortebiorx.com[/url]) (NASDAQ: FBRX), a clinical-stage biopharma

Statistically Significant FB102 Benefit Observed By Day 64 and Continued through Week 24FB102-Treate

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-sta

Forte Biosciences, Inc.$500,000,000Common StockPreferred StockDebt SecuritiesDepositary SharesWarran

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-sta

Forte Biosciences (NASDAQ:FBRX) reported quarterly losses of $(1.24) per share which missed the anal

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-sta

Forte Biosciences has rebounded from near-liquidation, raising $150m this week and advancing FB102,

U.S. stocks fell, Dow Jones down 100+ points. BlackBerry (NYSE:BB) reported strong Q4 results and sa

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical

Forte Biosciences, Inc. (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimm

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical

Forte Biosciences, Inc. (NASDAQ: FBRX - Get Free Report) was the target of some unusual options trad

Forte Biosciences (NASDAQ:FBRX) reported quarterly losses of $(1.45) per share which missed the anal

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-sta

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-sta

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-sta

Forte Biosciences (FBRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism abo

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-sta

  On Tuesday, 647 companies set new 52-week lows.

  On Tuesday, 386 stocks made new 52-week lows.

Companies Reporting Before The Bell • LightInTheBox Holding (NYSE:LITB) is estimated to report earn

  During Thursday, 849 stocks hit new 52-week lows.

Gainers